Trastuzumab (Tzb) was approved by the FDA as the first HER2-targeted therapeutics for treating patients with HER2-positive breast cancer, and its clinical use has led to a significant decline in breast cancer mortality [3]. This evidence concerns the gene ERBB2 and breast carcinoma.